Repare Therapeutics Inc (RPTX) Stock Price, Quote & News

Company Profile

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and...

Industry: Biotechnology

Sector: Healthcare

Phone: 857-412-7018

Website: www.reparerx.com

Address:

7171 Frederick-Banting, Building 2, Suite 270 St-Laurent, Montreal, Canada

Christyalmond Jul. 30 at 4:37 PM

$RPTX I am waiting for RP‑1664 data, bought small position

0 · Reply

Mr__Man Jul. 30 at 12:04 PM

$RPTX Cash per share is $2.88 on this bad boy, the only way is up

0 · Reply

DoublEEstocks Jul. 22 at 2:59 PM

$RPTX resistance at 1.53…can it break through?

0 · Reply

Mr__Man Jul. 18 at 9:33 AM

$RPTX A deep value stock with great news just out and fantastic prospects ahead, I'm in

1 · Reply

dontfollowme22 Jul. 17 at 1:59 PM

$RPTX is ready for fast flight ✈️

0 · Reply

DoublEEstocks Jul. 16 at 6:59 PM

$RPTX Think we will get some after hours movement? 🤞

0 · Reply

iSmith Jul. 16 at 5:53 PM

$RPTX Under the terms of the agreement, Repare will receive a $10 million upfront payment, and is eligible to receive up to $257 million in potential clinical, regulatory, commercial and sales milestones, including up to $5 million in potential near-term payments, and single-digit royalties on global net sales. $IOVA $EDIT

0 · Reply

Baazigar30 Jul. 16 at 4:23 PM

$RPTX Still here won’t leave untill my target or unless suddenly any bad news come

0 · Reply

LabPsycho Jul. 16 at 1:48 PM

$RPTX Giving away your main asset for a fraction of your existing cash is not a good look IMO.

3 · Reply

GSP Jul. 16 at 1:18 PM

$GAME $BTCS $NUWE $DTST $RPTX

0 · Reply

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

May 13, 2025, 4:05 PM EDT - 2 months ago

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results

May 1, 2025, 7:00 AM EDT - 3 months ago

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

May 1, 2025, 7:00 AM EDT - 3 months ago

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

Apr 25, 2025, 1:00 PM EDT - 3 months ago

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

Mar 31, 2025, 4:39 PM EDT - 4 months ago

Repare Therapeutics Announces Leadership Transitions

Mar 7, 2025, 4:05 PM EST - 5 months ago

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 3, 2025, 7:05 AM EST - 5 months ago

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 9, 2025, 4:05 PM EST - 7 months ago

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Dec 13, 2024, 12:09 PM EST - 8 months ago

Why Is Repare Therapeutics Stock Trading Lower On Friday?

Dec 12, 2024, 4:20 PM EST - 8 months ago

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Dec 10, 2024, 4:05 PM EST - 8 months ago

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Nov 12, 2024, 7:05 AM EST - 9 months ago

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Nov 7, 2024, 7:05 AM EST - 9 months ago

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

Oct 23, 2024, 6:05 AM EDT - 10 months ago

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

Oct 14, 2024, 7:05 AM EDT - 10 months ago

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

Sep 30, 2024, 4:05 PM EDT - 10 months ago

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting

Sep 23, 2024, 7:05 AM EDT - 11 months ago

Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers

Sep 13, 2024, 7:00 AM EDT - 11 months ago

Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024

Aug 30, 2024, 6:13 PM EDT - 11 months ago

Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data

Aug 28, 2024, 4:05 PM EDT - 11 months ago

Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio

Aug 27, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results

Jun 26, 2024, 10:30 AM EDT - 1 year ago

Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI

Jun 12, 2024, 7:00 AM EDT - 1 year ago

Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib

Jun 10, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial

Jun 4, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer

Jun 3, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 29, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024

May 7, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

Apr 30, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition

Apr 30, 2024, 7:05 AM EDT - 1 year ago

Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition

Apr 26, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Appoints Steven H. Stein, M.D.

Mar 21, 2024, 10:00 AM EDT - 1 year ago

Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Feb 28, 2024, 7:05 AM EST - 1 year ago

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 15, 2024, 7:05 AM EST - 1 year ago

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664

Feb 12, 2024, 4:05 PM EST - 1 year ago

Repare Therapeutics to Regain Global Rights to Camonsertib

Jan 25, 2024, 7:00 AM EST - 1 year ago

Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment

Jan 8, 2024, 7:00 AM EST - 1 year ago

Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones

Jan 4, 2024, 4:10 PM EST - 1 year ago

Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer

Jan 4, 2024, 4:05 PM EST - 1 year ago

Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer

Dec 29, 2023, 4:05 PM EST - 1 year ago

Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans

Nov 15, 2023, 7:00 AM EST - 1 year ago

Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor

Nov 9, 2023, 7:00 AM EST - 1 year ago

Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Nov 7, 2023, 7:00 AM EST - 1 year ago

Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast

Christyalmond Jul. 30 at 4:37 PM

$RPTX I am waiting for RP‑1664 data, bought small position

0 · Reply

Mr__Man Jul. 30 at 12:04 PM

$RPTX Cash per share is $2.88 on this bad boy, the only way is up

0 · Reply

DoublEEstocks Jul. 22 at 2:59 PM

$RPTX resistance at 1.53…can it break through?

0 · Reply

Mr__Man Jul. 18 at 9:33 AM

$RPTX A deep value stock with great news just out and fantastic prospects ahead, I'm in

1 · Reply

dontfollowme22 Jul. 17 at 1:59 PM

$RPTX is ready for fast flight ✈️

0 · Reply

DoublEEstocks Jul. 16 at 6:59 PM

$RPTX Think we will get some after hours movement? 🤞

0 · Reply

iSmith Jul. 16 at 5:53 PM

0 · Reply

Baazigar30 Jul. 16 at 4:23 PM

$RPTX Still here won’t leave untill my target or unless suddenly any bad news come

0 · Reply

LabPsycho Jul. 16 at 1:48 PM

$RPTX Giving away your main asset for a fraction of your existing cash is not a good look IMO.

3 · Reply

GSP Jul. 16 at 1:18 PM

$GAME $BTCS $NUWE $DTST $RPTX

0 · Reply

paddyTC Jul. 16 at 12:45 PM

$RPTX we’re open for business, new partner is very strong financially with history of successful blockbuster drugs.

0 · Reply

GSP Jul. 16 at 12:44 PM

Updated gapper list: $GAME $BTCS $NUWE $DTST $RPTX .

0 · Reply

GSP Jul. 16 at 12:09 PM

Gap play watch list for today (so far): $GAME $BTCS $NUWE $DTST $RPTX .

0 · Reply

HieronymusHole Jul. 16 at 10:49 AM

$RPTX enters deal worth about 3,300 ethereum upfront with potential for over 2,000 bitcoins worth of revenue.

1 · Reply

GSP Jul. 16 at 10:38 AM

Early look at morning gappers: $GAME $BTCS $NUWE $DTST $RPTX .

0 · Reply

Thestocktraderhubzee Jul. 16 at 10:02 AM

WATCHLIST JUL 16 2025. $EQT Homer City Redevelopment Taps EQT To Power 4.4 GW Natural Gas Facility For Upcoming AI And HPC Data Center Campus $RPTX Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement With Debiopharm For Lunresertib; Will Receive $10M Upfront Payment And Up To $257M In Potential Milestones $NUWE Nuwellis shares are trading higher after the company announced it secured a U.S. patent for an extracorporeal blood filtering machine and methods. $KVUE Citigroup Maintains Neutral on Kenvue, Lowers Price Target to $22 $LRFC Portman Ridge Finance Corporation Closes Previously Announced Merger With Logan Ridge Finance Corporation

0 · Reply